[NMR tomography of the liver with the new contrast agent Gd-BOPTA. The results of an in-vivo phase-I test].
A phase 1 study on 8 normals has been carried out to determine the effectiveness and safety during MRI of a new hepatobiliary contrast medium Gd-BOPTA for causing enhancement of the upper abdominal organs. Gradient echo sequences (flash), T1 and T2-weighted spin echo sequences and turbo-flash sequences were used. The contrast medium was given as a single infusion in various concentrations (0.005, 0.05, 0.1, and 0.2 mmol/kg body weight). Optimal contrast of liver parenchyma was obtained with a dose of 0.05-0.1 mmol/kg body weight, resulting in contrast increase of 149.1% during gradient echo sequences and 107.8% during T1 spin echo sequences. In general, the increased contrast lasted for about two hours. Because of the biliary and renal excretion there was an enormous increase in signal intensity of the bile ducts and a significant increase in the kidneys and ureters. The results of the first in-vivo trial of Gd-BOPTA encourages the performance of further clinical studies of this new hepatobiliary contrast medium.
Vogl
T J
TJ
Radiologische Klinik, Universität München.
Pegios
W
W
Waitzinger
J
J
Pirovano
G
G
Balzer
J
J
Lissner
J
J
D000085:Acetates / Q000008:administration & dosage; D003287:Contrast Media / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005682:Gadolinium / Q000008:administration & dosage; D005704:Gallbladder / Q000473:pathology; D006801:Humans; D007668:Kidney / Q000473:pathology; D008099:Liver / Q000473:pathology*; D008279:Magnetic Resonance Imaging / Q000295:instrumentation / Q000379:methods*; D008536:Meglumine / Q000031:analogs & derivatives*; D009942:Organometallic Compounds / Q000008:administration & dosage; D013154:Spleen / Q000473:pathology; D013997:Time Factors
D000085:Acetates; D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine; D005682:Gadolinium
Kernspintomographie der Leber mit dem neuen Kontrastmittel Gd-BOPTA. Ergebnisse einer In-vivo-Phase-I-Prüfung.